Clinical Trial Update: Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating toripalimab in combination with rituximab for relapsed/refractory CD20-positive diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Diffuse Large B-cell Lymphoma, Rituximab | Phase 2 | Status: UNKNOWN